Imiphumela mihle kubathuthukisi bokuhlolwa kwe-antigen, abone isidingo sehla ngemva kokwethulwa komgomo.
Ucwaningo oluncane oluxhaswe yiNational Institutes of Health (NIS) luthole ukuthi i-Covid-19 lateral flow test (LFT) isebenza kahle njengokuhlolwa kwe-polymerase chain reaction (PCR) ekutholeni ukutheleleka kwe-SARS-CoV-2.Kwenziwa njalo ezinsukwini ezintathu Ukuhlolwa okukodwa.
Ukuhlolwa kwe-PCR kuthathwa njengezinga legolide lokuhlonza ukutheleleka nge-Covid-19, kodwa ukusetshenziswa kwazo kabanzi njengamathuluzi okuhlola kunomkhawulo ngoba kudinga ukucutshungulwa elabhorethri futhi imiphumela ingathatha izinsuku ezimbalwa ukufinyelela iziguli.
Ngokuphambene, i-LFT inganikeza imiphumela emizuzwini eyi-15, futhi abasebenzisi abadingi nokuthi bahambe ekhaya.
Abacwaningi abaxhumene ne-NIH Diagnostic Rapid Acceleration Programme babike imiphumela yabantu abangama-43 abangenwe yi-Covid-19.Abahlanganyeli bebevela eNyuvesi yase-Illinois e-Urbana-Champaign (UIUC) SHIELD Illinois Covid-19 screening program.Kungenzeka ukuthi bazihlolele ukuthi bane-HIV noma bebesondelene nabantu abahlolelwe ukuthi bane-HIV.
Abahlanganyeli bangeniswa phakathi nezinsuku ezimbalwa zokuchayeka kugciwane, futhi imiphumela yokuhlolwa yayingenayo ezinsukwini ezingu-7 ngaphambi kokubhaliswa.
Bonke banikeze amasampula amathe kanye nezinhlobo ezimbili zama-swabs amakhala izinsuku eziyi-14 zilandelana, zase zicutshungulwa yi-PCR, LFT, kanye nesiko legciwane eliphilayo.
Isiko legciwane kuyinqubo esebenza kakhulu futhi ebiza kakhulu engasetshenziswa ekuhloleni i-Covid-19, kodwa isiza ukucacisa kakhulu uhlobo lwegciwane esampula.Lokhu kungasiza abacwaningi balinganisele ukuqala kanye nobude besikhathi sokutheleleka nge-Covid-19.
UChristopher Brooke, onguSolwazi we-Molecular and Cell Biology e-UIUC, uthe: “Ukuhlola okuningi kuthola ufuzo oluhlobene naleli gciwane, kodwa lokhu akusho ukuthi kunegciwane eliphilayo.Okuwukuphela kwendlela yokunquma ukuthi likhona yini igciwane eliphilayo nelithelelanayo ukwenza isinqumo sokungenwa yigciwane noma isiko.”
Ngemuva kwalokho, abacwaningi baqhathanisa izindlela ezintathu zokutholwa kwegciwane le-Covid-19-ukutholwa kwe-PCR yamathe, ukutholwa kwe-PCR kwamasampula ekhala, kanye nokutholwa kwe-antigen okusheshayo ye-Covid-19 yamasampula amakhala.
Imiphumela yesampula yamathe yenziwa ukuhlolwa okugunyaziwe kwe-PCR okusekelwe ematheni athuthukiswe i-UIUC, ebizwa ngokuthi i-covidSHIELD, engakhiqiza imiphumela cishe ngemva kwamahora angu-12.Ukuhlola okuhlukile kwe-PCR kusetshenziswa idivayisi ye-Abbott Alinity kusetshenziselwa ukuthola imiphumela kuma-swabs wamakhala.
Ukutholwa kwe-antigen ngokushesha kwenziwa kusetshenziswa i-Quidel Sofia SARS antigen fluorescence immunoassay, LFT, egunyazwe ukunakekelwa ngokushesha futhi engaveza imiphumela ngemva kwemizuzu engu-15.
Ngemuva kwalokho, abacwaningi babala ukuzwela kwendlela ngayinye ekutholeni i-SARS-CoV-2, baphinde balinganisa ubukhona begciwane eliphilayo kungakapheli amasonto amabili okutheleleka kokuqala.
Bathole ukuthi ukuhlolwa kwe-PCR kuzwela kakhulu kunokuhlolwa okusheshayo kwe-Covid-19 antigen lapho kuhlolwa igciwane ngaphambi kwesikhathi sokutheleleka, kodwa baveza ukuthi imiphumela ye-PCR ingathatha izinsuku ezimbalwa ukubuyiselwa kumuntu ohlolwayo.
Abacwaningi babale ukuzwela kokuhlolwa ngokusekelwe ekuvameni kokuhlolwa futhi bathola ukuthi ukuzwela kokuthola ukutheleleka kungaphezulu kuka-98% lapho ukuhlolwa kwenziwa njalo ezinsukwini ezintathu, noma ngabe ukuhlolwa okusheshayo kwe-Covid-19 antigen noma ukuhlolwa kwe-PCR.
Lapho behlola imvamisa yokuthola kanye ngesonto, ukuzwela kokutholwa kwe-PCR yomgodi wamakhala namathe kwakusephezulu, cishe u-98%, kodwa ukuzwela kokutholwa kwe-antigen kwehle kwaya ku-80%.
Imiphumela ikhombisa ukuthi ukusebenzisa isivivinyo esisheshayo se-Covid-19 antigen okungenani kabili ngeviki ekuhlolweni kwe-Covid-19 kunokusebenza okufanayo nokuhlolwa kwe-PCR futhi kukhulisa amathuba okuthola umuntu onaleli gciwane ekuqaleni kwesifo.
Le miphumela izokwamukelwa ngabathuthukisi abasheshayo be-antigen, abasanda kubika ukuthi isidingo sokuhlolwa kwe-Covid-19 sehlile ngenxa yokwethulwa komgomo.
Kokubili ukuthengiswa kwe-BD ne-Quidel emalini yakamuva bekuphansi kunalokho obekulindelwe ngabahlaziyi, kwathi ngemuva kokuba isidingo sokuhlolwa kwe-Covid-19 sehle kakhulu, u-Abbott wehlisa umbono wakhe ka-2021.
Ngesikhathi sobhubhane, odokotela abahambisani nokusebenza kwe-LFT, ikakhulukazi ezinhlelweni zokuhlola ezinkulu, njengoba zivamise ukwenza kabi ekutholeni izifo ezingenazimpawu.
Ucwaningo olushicilelwe yi-US Centers for Disease Control and Prevention ngoJanuwari lubonise ukuthi ukuhlolwa okusheshayo kuka-Abbott i-BinaxNOW kungase kugeje cishe izingxenye ezimbili kwezintathu zezifo ezingenazimpawu.
Ngasikhathi sinye, ukuhlolwa kwe-Innova okwasetshenziswa e-UK kukhombise ukuthi ukuzwela ezigulini ezinezimpawu ze-Covid-19 kwakungama-58% kuphela, kanti imininingwane yomshayeli elinganiselwe ikhombisa ukuthi ukuzwela kwe-asymptomatic kwakungama-40 kuphela%.
Isikhathi sokuthumela: Jul-05-2021